PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsSelegiline
Selegiline
Emsam, Selegiline, Zelapar (selegiline) is a small molecule pharmaceutical. Selegiline was first approved as Selegiline hydrochloride on 1989-06-05. It is used to treat alzheimer disease, attention deficit disorder with hyperactivity, depressive disorder, parkinson disease, and schizophrenia in the USA. The pharmaceutical is active against amine oxidase [flavin-containing] B. In addition, it is known to target amine oxidase [flavin-containing] A.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
mental disordersD001523
Trade Name
FDA
EMA
Emsam, Selegiline, Zelapar (discontinued: Eldepryl, Selegiline)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Selegiline hydrochloride
Tradename
Company
Number
Date
Products
ZELAPARBausch Health CompaniesN-021479 RX2006-06-14
1 products, RLD, RS
Show 2 discontinued
Selegiline
Tradename
Company
Number
Date
Products
EMSAMSomerset PharmaN-021336 RX2006-02-27
3 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
emsamNew Drug Application2020-05-15
selegiline hydrochlorideANDA2025-02-28
zelaparNew Drug Application2021-06-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
parkinson diseaseEFO_0002508D010300G20
alzheimer diseaseEFO_0000249D000544F03
schizophreniaEFO_0000692D012559F20
attention deficit disorder with hyperactivityEFO_0003888D001289F90
depressive disorderEFO_1002014D003866F32.A
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N04: Anti-parkinson drugs
— N04B: Dopaminergic agents
— N04BD: Mao b inhibitors, dopaminergic anti-parkinson drugs
— N04BD01: Selegiline
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Parkinson diseaseD010300EFO_0002508G20———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSelegiline
INNselegiline
Description
(-)-selegiline is a selegiline and a terminal acetylenic compound. It has a role as a geroprotector. It is a conjugate base of a (-)-selegiline(1+).
Classification
Small molecule
Drug classMonoamine oxidase (MAO) inhibitors, type B
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
C#CCN(C)[C@H](C)Cc1ccccc1
Identifiers
PDB—
CAS-ID14611-51-9
RxCUI—
ChEMBL IDCHEMBL972
ChEBI ID9086
PubChem CID26757
DrugBankDB01037
UNII ID2K1V7GP655 (ChemIDplus, GSRS)
Target
Agency Approved
MAOB
MAOB
Organism
Homo sapiens
Gene name
MAOB
Gene synonyms
NCBI Gene ID
4129
Protein name
amine oxidase [flavin-containing] B
Protein synonyms
adrenalin oxidase, MAO, brain, MAO, platelet, MAO-B, Monoamine oxidase type B, tyramine oxidase
Uniprot ID
Q7Z6S2
Mouse ortholog
Maob (109731)
amine oxidase [flavin-containing] B (Q8C0B2)
Alternate
MAOA
MAOA
Organism
Homo sapiens
Gene name
MAOA
Gene synonyms
NCBI Gene ID
4128
Protein name
amine oxidase [flavin-containing] A
Protein synonyms
MAO-A, Monoamine oxidase type A
Uniprot ID
Q16426
Mouse ortholog
Maoa (17161)
amine oxidase [flavin-containing] A (Q8K0Z8)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Selegiline
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,429 documents
View more details
Safety
Black-box Warning
Black-box warning for: Emsam
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
2,265 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use